Karakousis C P, Didolkar M S, Lopez R, Baffi R, Moore R, Holyoke E D
Cancer Treat Rep. 1979 Nov-Dec;63(11-12):1739-43.
Sixty-one patients with stage I or II (lymph node involvement) malignant melanoma were prospectively randomized into a control group receiving surgical treatment only (consisting of wide excision of primary and regional node dissection) and a group receiving the same surgical treatment plus adjuvant therapy with DTIC and Corynebacterium parvum. Followup times ranged from 1 1/2 to 4 years. Among the 29 patients in the surgical control group, there were five hematogenous recurrences and one regional recurrence and four patients have died. Among the 32 patients in the treatment group, there were 13 hematogenous recurrences and two regional recurrences and ten patients have died. However, the control group had six patients with involved lymph nodes while the treatment group had 15 patients in this category. It appears that although the combination of DTIC and C. parvum was well-tolerated, it did not reduce the recurrence and mortality rates.
61例I期或II期（伴有淋巴结受累）恶性黑色素瘤患者被前瞻性随机分为两组，一组为仅接受手术治疗的对照组（包括原发灶广泛切除和区域淋巴结清扫），另一组为接受相同手术治疗并加用达卡巴嗪（DTIC）和短小棒状杆菌辅助治疗的组。随访时间为1.5至4年。手术对照组的29例患者中，有5例血行复发、1例区域复发，4例死亡。治疗组的32例患者中，有13例血行复发、2例区域复发，10例死亡。然而，对照组有6例淋巴结受累患者，而治疗组此类患者有15例。看来，尽管DTIC和短小棒状杆菌联合用药耐受性良好，但并未降低复发率和死亡率。
